Psoriatic Arthritis Treatment Global Market Report 2021 Featuring AbbVie, Amgen, J&J, BMS, Celgene, Novartis, Eli Lilly And Co, Pfizer, UCB Biosciences, and Hoffmann La Roche – ResearchAndMarkets.com

Psoriatic Arthritis Treatment Global Market Report 2021 Featuring AbbVie, Amgen, J&J, BMS, Celgene, Novartis, Eli Lilly And Co, Pfizer, UCB Biosciences, and Hoffmann La Roche – ResearchAndMarkets.com




Psoriatic Arthritis Treatment Global Market Report 2021 Featuring AbbVie, Amgen, J&J, BMS, Celgene, Novartis, Eli Lilly And Co, Pfizer, UCB Biosciences, and Hoffmann La Roche – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Psoriatic Arthritis Treatment Global Market Report 2021: COVID-19 Growth and Change to 2030” report has been added to ResearchAndMarkets.com’s offering.

The global psoriatic arthritis treatment market is expected to grow from $7.26 billion in 2020 to $7.89 billion in 2021 at a compound annual growth rate (CAGR) of 8.7%. The market is expected to reach $11.34 billion in 2025 at a CAGR of 9%.

Major players in the psoriatic arthritis treatment market are AbbVie, Amgen, Johnson & Johnson, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly And Company, Pfizer, UCB Biosciences Inc, and Hoffmann La Roche Ltd.

The psoriatic arthritis treatment market consists of the sale of psoriatic arthritis drugs used for the treatment of psoriatic arthritis by entities producing drugs for psoriatic arthritis. Psoriasis arthritis is a chronic inflammatory joint disease that is associated with psoriasis, whose symptoms vary from person to person.

The psoriatic arthritis treatment market covered in this report is segmented by drug class into nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDS), biologics, others. It is also segmented by route of administration into oral, parenteral, topical and by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies.

The development of novel drugs such as Janus kinase (JAK) inhibitors for treating psoriatic arthritis is shaping the market. Janus kinase (JAK) inhibitors are orally administered small molecules emerging as a novel treatment for psoriatic arthritis patients. There are three JAK inhibitors approved for the treatment of autoimmune diseases – tofacitinib, baricitinib, and upadacitinib.

Among them, Xeljanz (tofacitinib) and Xeljanz (tofacitinib) XR are the first Janus kinase (JAK) inhibitors that have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). They are used to treat adult patients with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

In June 2020, AbbVie, a leading US-based pharmaceutical company has announced that it has applied for the approval of upadacitinib (RINVOQ), a JAK inhibitor with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Otezla (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis and active psoriatic arthritis.

The rise in the prevalence of psoriasis & psoriatic arthritis disease boosted the growth of the psoriatic arthritis treatment market. Psoriasis (Pso) and psoriatic arthritis (PsA) are inflammatory disorders that can severely impair health and quality of life. Psoriasis is associated with inflammatory arthritis, known as psoriatic arthritis (PsA), with an incidence of 30% in psoriatic patients.

According to the national psoriasis foundation, more than 8 million Americans have psoriasis. According to the National Psoriasis Foundation, in the USA, about 30% of people with psoriasis also develop psoriatic arthritis. Thus, an increase in the prevalence of psoriasis & psoriatic arthritis disease drives market growth.

Key Topics Covered:

1. Executive Summary

2. Psoriatic Arthritis Treatment Market Characteristics

3. Psoriatic Arthritis Treatment Market Trends and Strategies

4. Impact Of COVID-19 On Psoriatic Arthritis Treatment

5. Psoriatic Arthritis Treatment Market Size and Growth

5.1. Global Psoriatic Arthritis Treatment Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. Global Psoriatic Arthritis Treatment Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Psoriatic Arthritis Treatment Market Segmentation

6.1. Global Psoriatic Arthritis Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Disease-modifying anti-rheumatic drugs (DMARDs)
  • Biologics
  • Others

6.2. Global Psoriatic Arthritis Treatment Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Oral
  • Parenteral
  • Topical

6.3. Global Psoriatic Arthritis Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Psoriatic Arthritis Treatment Market Regional and Country Analysis

7.1. Global Psoriatic Arthritis Treatment Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Psoriatic Arthritis Treatment Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Novartis
  • Eli Lilly and Company
  • Pfizer
  • UCB Biosciences Inc
  • Hoffmann La Roche Ltd.
  • Merck & Co
  • AstraZeneca
  • Sanofi
  • Otsuka Pharmaceutical
  • Sumitomo Dainippon Pharma Co
  • Bayer
  • Abbott Laboratories
  • Eisai Inc
  • Janssen Biotech
  • Bausch Health Companies

For more information about this report visit https://www.researchandmarkets.com/r/77czmi

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900